Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer

Vitamin D promotes the differentiation of prostate cancer cells, maintains the differentiated phenotype of prostate epithelial cells, and can induce prostate cancer cell death, raising the possibility that vitamin D deficiency over time promotes the progression of subclinical prostate cancer to clinical disease. The investigators propose to conduct a clinical study aimed at measuring the efficacy of vitamin D3 (4000IU/day) supplementation in Veterans diagnosed with low-risk, early-stage prostate cancer, who elect to have their disease monitored through active surveillance. The successful completion of this proposed clinical study will allow us to determine whether correcting vitamin D deficiency in Veterans diagnosed with early-stage prostate cancer will prevent progression of their disease and improve their prognosis.

Sex

Male

Minimum age

19 Years

Maximum age

85 Years

Inclusion Criteria:

* Male Veterans (\> 18 years of age) recently diagnosed with low-risk PCa (histologically documented adenocarcinoma of the prostate)
* A serum PSA value of up to 10.0 ng/ml, and a Gleason score of six or less (three or less in either architectural pattern)
* For the purpose of eligibility, these additional criteria will be verified: \*serum creatinine 2.0 mg/dL

  * serum phosphate (measured as phosphorus) \> 2.3 and \< 4.8 mg/dL
  * serum calcium \> 8.5 and \< 10.5 mg/dL

Exclusion Criteria:

* Subjects with any concurrent malignancy, except non-melanoma skin cancer
* Subjects with a history of sarcoidosis
* Subjects with a history of high-dose (1,000 IU per day) vitamin D supplementation
* Subjects with a history of hypercalcemia
* Subjects who use lithium as a medication